Alzoubi et al. investigated the role of HDAC2 in drug resistance and its impact on CRC cell lines with varied p53 mutation states (wt, null or mutated), demonstrating that increased expression of HDAC2 correlated with drug resistance, and depletion by shRNA or inhibition by HDACi sensitized the multidrug resistance of the p53 mutated HT-29 cell line to chemotherapeutic drugs such as 5-FU and oxaliplatin [137]. The gene discussed is TP53; the disease is colorectal carcinoma.